Virtual screening in drug-likeness and structure/activity relationship of pyridazine derivatives as Anti-Alzheimer drugs

Atkinson, 2002, Lipophilicity and other parameters affecting brain penetration, Cent. Nerv. Syst. Agents. Med. Chem., 2, 229, 10.2174/1568015023358058

Bazooyar, 2013, Molecular modelling of cellulose dissolution, J. Comput. Theor. Nanosci., 10, 2639, 10.1166/jctn.2013.3263

Belaidi, 2015, In Silico Approach for Conformational Analysis, Drug-Likeness Properties and Structure Activity Relationships of 12-Membered Macrolides, J. Comput. Theor. Nanosci., 12, 4855, 10.1166/jctn.2015.4451

Contreras, 2001, Design, synthesis, and structure− activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl) ethylamino] pyridazine derivatives as acetylcholinesterase inhibitors, J. Med. Chem., 44, 2707, 10.1021/jm001088u

Contreras, 1999, Aminopyridazines as acetylcholinesterase inhibitors, J. Med. Chem., 42, 730, 10.1021/jm981101z

Elagawany, 2013, Synthesis and antiproliferative effects of 5, 6-disubstituted pyridazin-3 (2H)-ones designed as conformationally constrained combretastatin A-4 analogues, Anticancer Agents Med. Chem., 13, 1133, 10.2174/1871520611313070018

El-Sayed, 2009, Synthesis and antibacterial activity of some glucosyl-and ribosyl-pyridazin-3-ones, Nucleos. Nucleo. Nucl., 28, 184, 10.1080/15257770902831011

Fichert, 2003, A structure–permeability study of small drug-like molecules, Bioorg. Med. Chem. Lett., 13, 719, 10.1016/S0960-894X(02)01035-1

Francis, 1999, The cholinergic hypothesis of Alzheimer’s disease, J. Neurol. Neurosurg. Psychiatry, 66, 137, 10.1136/jnnp.66.2.137

Ghose, 2011, Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery, ACS Chem. Neurosci., 3, 50, 10.1021/cn200100h

Hopkins, 2004, Ligand efficiency: a useful metric for lead selection, Drug Discov. Today, 9, 430, 10.1016/S1359-6446(04)03069-7

Jann, 2000, Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease, Pharmacother. J. Hum. Pharmacol. Drug Ther., 20, 1, 10.1592/phco.20.1.1.34664

Johnson, 2009, Using the Golden Triangle to optimize clearance and oral absorption, Bioorg. Med. Chem. Lett., 19, 5560, 10.1016/j.bmcl.2009.08.045

Kerassa, 2016, Investigations on Molecular Structure, Electronic Properties, NLO Properties and Comparison of Drug-Likeness of Triazolothiadiazole Derivatives by Quantum Methods and QSAR Analysis, Reviews. Theor. Sci., 4, 85, 10.1166/rits.2016.1050

Keserü, 2009, The influence of lead discovery strategies on the properties of drug candidates, Nat. Rev. Drug Discov., 8, 203, 10.1038/nrd2796

Leeson, 2007, The influence of drug-like concepts on decision-making in medicinal chemistry, Nat. Rev. Drug Discov., 6, 881, 10.1038/nrd2445

Lipinski, 1997, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev., 23, 3, 10.1016/S0169-409X(96)00423-1

Martin, 2005, A bioavailability score, J. Med. Chem., 48, 3164, 10.1021/jm0492002

Melkemi, 2014, Structure-property relationships and quantitative structure-activity relationship modeling of detoxication properties of some 1, 2-dithiole-3-thione derivatives, J. Comput. Theor. Nanosci., 11, 801, 10.1166/jctn.2014.3431

Pajouhesh, 2005, Medicinal chemical properties of successful central nervous system drugs, Neuro Rx., 2, 541, 10.1602/neurorx.2.4.541

Palm, 1997, Polar molecular surface properties predict the intestinal absorption of drugs in humans, Pharmacol. Res., 14, 568, 10.1023/A:1012188625088

Patani, 1996, Bioisosterism: A Rational Approach in Drug Design, Chem. Rev., 96, 3147, 10.1021/cr950066q

Prince, M., Comas-Herrera, A., Knapp, M., Guerchet, M., Karagiannidou, M., 2016. World Alzheimer report: The Global Economic Impact of Dementia. Alzheimer’s Disease International.

Rathish, 2012, Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(p-sulfamylphenyl)-pyridazin-3 (2H)-ones, Eur. J. Med. Chem., 49, 304, 10.1016/j.ejmech.2012.01.026

Reddy, 2007, Virtual screening in drug discovery-a computational perspective, Curr. Protein Pept. Sci., 8, 329, 10.2174/138920307781369427

Refaat, 2007, Synthesis and anti-inflammatory activity of certain piperazinylthienylpyridazine derivatives, Arch. Pharmacol. Res., 30, 803, 10.1007/BF02978828

Ritchie, 2012, The developability of heteroaromatic and heteroaliphatic rings–do some have a better pedigree as potential drug, Med. Chem. Comm., 3, 1062, 10.1039/c2md20111a

Rollinger, 2004, Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products, J. Med. Chem., 47, 6248, 10.1021/jm049655r

Salah, 2015, Molecular Geometry, Electronic Properties, MPO Methods and Structure Activity/Property Relationship Studies of 1, 3, 4-Thiadiazole Derivatives by Theoretical Calculations, Rev. Theor. Sci., 3, 355, 10.1166/rits.2015.1040

Segall, 2012, Multi-parameter optimization: identifying high quality compounds with a balance of properties, Curr. Pharm. Des., 18, 1292, 10.2174/138161212799436430

Siddiqui, 2011, Triazole incorporated pyridazinones as a new class of antihypertensive agents: design, synthesis and in vivo screening, Bioorg. Med. Chem. Lett., 21, 1023, 10.1016/j.bmcl.2010.12.028

Van de Waterbeemd, 1998, Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors, J. Drug Target., 6, 151, 10.3109/10611869808997889

Veber, 2002, Molecular properties that influence the oral bioavailability of drug candidates, J. Med. Chem., 45, 2615, 10.1021/jm020017n

Wager, 2010, Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes, ACS Chem. Neurosci., 1, 420, 10.1021/cn100007x

Wager, 2010, Moving beyond rules: the development of a central nervous system multiparameter optimization(CNS MPO) approach to enable alignment of druglike properties, ACS Chem. Neurosci., 1, 435, 10.1021/cn100008c

Waring, 2009, Defining optimum lipophilicity and molecular weight ranges for drug candidates molecular weight dependent lower logD limits based on permeability, Bioorg. Med. Chem. Lett., 19, 2844, 10.1016/j.bmcl.2009.03.109

Wermuth, 2011, Are pyridazines privileged structures?, Med. Chem. Comm., 2, 935, 10.1039/c1md00074h

Zhao, 2002, Rate-limited steps of human oral absorption and QSAR studies, Pharmacol. Res., 19, 1446, 10.1023/A:1020444330011